News

Today I will provide you with an update on the launch of NEXTSTELLIS our novel contraceptive which received FDA approval earlier this year together with some comments around our evolving specialty products business model and our outlook.

Mayne Pharma Group Limited (ASX: MYX) has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) in relation to its abbreviated new drug application (ANDA) for a generic version of NUVARING.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Carolyn Myers, M.B.A., Ph.D. has accepted an invitation to join the Board of Mayne Pharma Group Limited, effective immediately

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of isotretinoin capsules, 10 mg, 20 mg, 30 mg and 40 mg in the United States.

Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents.

2021 Full Year Results Media Release

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr Frank Condella, a US resident, will be appointed Chairman with effect from 30 September 2021.

Mayne Pharma Group Limited (ASX: MYX) has been served with a class action proceeding against Mayne Pharma in the Supreme Court of Victoria.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has licensed the Australian rights to SOLARAZE®